Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Oncol. 2009 Jan;16(1):59-61.

Targeting mTOR-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses.

Abstract

Cancer cells are characterized by aberrant growth arising from deregulated signalling pathways. The mammalian target of rapamycin (mTOR) pathway integrates multiple growth signals coming from both intracellular and extracellular cues. In this short review, we summarize what is known about the efficacy of targeting the mTOR pathway to treat cancer patients, and we explain the rationale behind promising new inhibitors that could show more potent tumour growth inhibition than did the first generation of these drugs.

KEYWORDS:

Cell signalling; Fkbp12; Lkb1; mtor; rapamycin; tumour growth

PMID:
19229373
PMCID:
PMC2644626
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multimed Inc. Icon for PubMed Central
    Loading ...
    Support Center